Authors
Flotte, Terence R.Document Type
EditorialPublication Date
2019-01-10
Metadata
Show full item recordAbstract
The continued rapid progress of human gene and cell therapy in the latter half of the 2010s is fueled by the maturation of gene and cell therapy platforms, improvements in manufacturing capabilities, and an investment climate in the United States and Europe that has been very favorable to biotechnology and pharmaceutical industries engaged in gene therapy product development. Many of these factors are likely to continue in 2019, although some of them may bear further examination. Given what is known in late 2018, the following predictions are put forward for consideration.Source
Hum Gene Ther. 2019 Jan;30(1):1-2. doi: 10.1089/hum.2018.29080.trf. Link to article on publisher's site
DOI
10.1089/hum.2018.29080.trfPermanent Link to this Item
http://hdl.handle.net/20.500.14038/43688PubMed ID
30628861Related Resources
ae974a485f413a2113503eed53cd6c53
10.1089/hum.2018.29080.trf